Recapturing disease response: A phase 2 study of carfilzomib 56 mg/m2 in patients with relapsed or refractory multiple myeloma who have progressed on carfilzomib 27 mg/m2.
Kevin BarleyLarysa J SanchezHearn J ChoSamir ParekhDeepu MadduriJoshua RichterLuis IsolaTalia GoldsteinAmishi DhadwalKatarzyna ZarychtaGillian Morgan SanchezDonna CatameroDaniel VerinaErika FlorendoMoon-Hee YumLisa LaJude GullieElaine ChanSundar JagannathAjai ChariPublished in: American journal of hematology (2019)